The frequent posting of concern lumping 2-73 in with both existing and proposed new Alzheimer’s drugs, in regard to the multitude of side effects each of these has, is understandable. It is presumed that all such drugs, necessarily, must have untoward side effects; therefore, so will 2-73 when used in humans.
This is an error. There is not a scintilla of evidence, in either animal or human trials, at efficacious dosages, that 2-73 has any side effects of consideration. In fact, it virtually has none whatsoever.
The reason for this is that 2-73 works very differently from other AD drugs. They a) reduce acetylcholinesterase decay, facilitating inter-neuron signaling (but only for a time), b) target removal of a-beta waste protein clusters or tau-tangles, or c) attempt to prompt the immune system to target and clean up the neurological wastes that are presumed to be (incorrectly) the root cause of AD symptoms.
Anavex 2-73 works entirely differently. In extremely low concentrations, it both crosses the blood/brain barrier and enters neurons, where it then remarkably restores normal endoplasmic rectulum/mitochondrial connections, allowing mitochondria to provide the ER with adequate ATP so proteins are normally processed and folded. In all of the neurodegenerative conditions 2-73 has been shown to be efficacious, the endoplasmic reticula (ER) have become physically and chemically detached from the energy-supplying mitochondria.
To summarize, 2-73 at effective doses simply fails to disrupt or interfere with any normal cellular or systemic process. It therefore has no known side effects.
Those who wish to base their AVXL investment decisions on the dismal prior records of failed or weak AD drugs are free to do so. But, as a biologist, I understand 2-73's unique biochemistry. No comparison whatsoever to any other AD drug.
